prucalopride succinate (motegrity) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem

Active Ingredient History

NOW
  • Now
Prucalopride, sold under brand names Resolor and Motegrity among others, is a medication acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements. Prucalopride was approved for medical use in the European Union in 2009, in Canada in 2011, in Israel in 2014, and in the United States in December 2018. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.   Wikipedia

Chemistry

  • SMILES: COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1
  • InChIKey: ZPMNHBXQOOVQJL-UHFFFAOYSA-N
  • Mol. Mass: 367.88
  • ALogP: 2.09
  • ChEMBL Molecules:
    prucalopride  
    prucalopride succinate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$10.6320 - $14.8328
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

prucalopride succinate | r-108512

Organizations (4)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Constipation (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Healthy Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue